{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:07:34Z","timestamp":1790082454353,"version":"4.0.1"},"reference-count":63,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vitiligo is an acquired depigmenting disorder resulting from melanocyte loss. Although drug-associated vitiligo has been increasingly reported following exposure to immunomodulatory, oncological and other pharmacological therapies, implicated drug classes, clinical patterns and underlying mechanisms remain incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Our aim was to systematically review reported cases of drug-associated vitiligo, identify implicated therapies, characterize clinical features and evaluate proposed pathogenic mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was conducted according to the PRISMA guidelines and a prospectively registered protocol (PROSPERO: CRD42025648719). PubMed, Embase Classic + Embase and Ovid MEDLINE ALL were searched from January 1975 to April 2025, with an updated PubMed search performed to January 2026. Studies reporting new-onset vitiligo following exposure to a pharmacological agent were included. Demographic, clinical, treatment and outcome data were extracted and synthesized narratively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 184 publications comprising 258 individual cases were included. The most frequently implicated drug classes were immune checkpoint inhibitors (72 of 258, 27.9%), topical immune modifiers and sensitizers (46 of 258, 17.8%), biologic immunomodulators (44 of 258, 17.1%) and targeted therapies (43 of 258, 16.7%). The most commonly reported agents were imiquimod 5% cream (n = 30), nivolumab (n = 30), diphenylcyclopropenone (n = 18), pembrolizumab (n = 17), interferon-\u03b1 (n = 17) and ribociclib (n = 16). Vitiligo most commonly involved the upper extremities (n = 127), face (n = 119) and trunk (n = 101). Among 256 cases with reported latency, vitiligo most frequently developed 3\u20136\u2005months following treatment initiation (66 of 256, 25.8%), although distinct temporal patterns were observed between therapeutic classes. Among malignancy-associated cases with available outcome data, favourable oncological outcomes were reported in 74 of 95 patients (78%), including 38 of 42 melanoma-associated cases (90%). Recurrent mechanistic themes included immune-mediated melanocyte destruction, direct melanocyte toxicity and local inflammatory triggering.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Drug-associated vitiligo represents a heterogeneous spectrum of disorders spanning multiple therapeutic classes. While recurrent clinical patterns and biologically plausible mechanisms support a contributory role for several drug classes, causality remains uncertain for many reported associations. Recognition of characteristic clinical and temporal patterns may improve patient counselling, inform treatment decisions and guide future pharmacovigilance and mechanistic research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag350","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T11:35:44Z","timestamp":1785670544000},"source":"Crossref","is-referenced-by-count":0,"title":["Drug-associated vitiligo: a systematic review of therapies, clinical patterns and mechanisms"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9497-0504","authenticated-orcid":false,"given":"Brent J","family":"Doolan","sequence":"first","affiliation":[{"name":"Department of Dermatology, St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 Hospital , London ,","place":["UK"]},{"name":"St John\u2019s Institute of Dermatology, School of Basic and Medical Biosciences, King\u2019s College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6609-2073","authenticated-orcid":false,"given":"John","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"2026092208161199300_llag350-B1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"2026092208161199300_llag350-B2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/978-981-95-3857-7_21","volume-title":"In: A Concise Guide to the Management of Vitiligo","author":"Sharma","year":"2026"},{"key":"2026092208161199300_llag350-B3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/bjd\/ljae133","article-title":"Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK","volume":"191","author":"Eleftheriadou","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026092208161199300_llag350-B4","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1111\/bjd.13642","article-title":"Topical monobenzyl ether of hydroquinone is an effective and safe treatment for depigmentation of extensive vitiligo in the medium term: a retrospective cohort study of 53 cases","volume":"172","author":"Tan","year":"2015","journal-title":"Br J Dermatol"},{"key":"2026092208161199300_llag350-B5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.det.2016.11.006","article-title":"Chemical-induced vitiligo","volume":"35","author":"Harris","year":"2017","journal-title":"Dermatol Clin"},{"key":"2026092208161199300_llag350-B6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jaad.2010.11.061","article-title":"Vitiligo: a comprehensive overview. Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up","volume":"65","author":"Alikhan","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2026092208161199300_llag350-B7","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3390\/cancers12071819","article-title":"Sex and gender disparities in melanoma","volume":"12","author":"Bellenghi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026092208161199300_llag350-B8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jdin.2024.10.005","article-title":"Association of vitiligo with immune-checkpoint inhibitor therapy: a systematic review","volume":"18","author":"Fleshner","year":"2025","journal-title":"JAAD Int"},{"key":"2026092208161199300_llag350-B9","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/ijc.70159","article-title":"Immune checkpoint inhibitor-induced vitiligo: a large-scale real world pharmacovigilance study","volume":"158","author":"Tang","year":"2026","journal-title":"Int J Cancer"},{"key":"2026092208161199300_llag350-B10","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1111\/1346-8138.14887","article-title":"Sarcoid-like reaction and vitiligo occurring after nivolumab therapy in a patient with metastatic melanoma","volume":"46","author":"Fukuchi","year":"2019","journal-title":"J Dermatol"},{"key":"2026092208161199300_llag350-B11","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3390\/curroncol31020083","article-title":"Vitiligo-like lesions as a predictor of response to immunotherapy in non-small cell lung cancer: comprehensive review and case series from a University Center","volume":"31","author":"Coelho","year":"2024","journal-title":"Curr Oncol"},{"key":"2026092208161199300_llag350-B12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000455972","article-title":"Post-finasteride adverse effects in male androgenic alopecia: a case report of vitiligo","volume":"30","author":"Motofei","year":"2017","journal-title":"Skin Pharmacol Physiol"},{"issue":"Suppl. 1","key":"2026092208161199300_llag350-B13","first-page":"AB297","article-title":"Vitiligo-like depigmentation in a patient with advanced melanoma","volume":"81","author":"Falto-Aizpurua","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2026092208161199300_llag350-B14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.lungcan.2017.04.019","article-title":"Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report","volume":"109","author":"Uenami","year":"2017","journal-title":"Lung Cancer"},{"key":"2026092208161199300_llag350-B15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4103\/jewd.jewd_64_24","article-title":"Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast","volume":"22","author":"Deb","year":"2025","journal-title":"J Egypt Womens Dermatol Soc"},{"key":"2026092208161199300_llag350-B16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jdcr.2024.11.002","article-title":"Topical ruxolitinib for treatment-induced vitiligo in a patient with metastatic melanoma","volume":"55","author":"Tasdogan","year":"2025","journal-title":"JAAD Case Rep"},{"key":"2026092208161199300_llag350-B17","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/ajco.13585","article-title":"Drug-induced vitiligo-like depigmentation from a CDK 4\/6 inhibitor","volume":"18","author":"Chan","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"2026092208161199300_llag350-B18","doi-asserted-by":"crossref","first-page":"e12923","DOI":"10.1111\/phpp.12923","article-title":"Men\u00e9ndez AD, Dom\u00ednguez Au\u00f1\u00f3n JD. Vitiligo-like depigmentation affecting sun-exposed areas caused by palbociclib","volume":"40","author":"P\u00e9rez","year":"2024","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2026092208161199300_llag350-B19","doi-asserted-by":"crossref","first-page":"1611115","DOI":"10.3389\/pore.2023.1611115","article-title":"Vitiligo-like lesions induced by cyclin-dependent kinase 4\/6 inhibitor palbociclib: a case report and literature review","volume":"29","author":"Gao","year":"2023","journal-title":"Pathol Oncol Res"},{"key":"2026092208161199300_llag350-B20","first-page":"9359086","article-title":"Development of asymmetric facial depigmentation in a patient treated with dasatinib with new-onset hypovitaminosis D: case report and review of the literature","volume":"2017","author":"Webb","year":"2017","journal-title":"Case Rep Dermatol Med"},{"key":"2026092208161199300_llag350-B21","doi-asserted-by":"crossref","first-page":"20020","DOI":"10.5070\/D31910020020","article-title":"Gefitinib-associated vitiligo: report in a man with parotid squamous cell carcinoma and review of drug-induced hypopigmentation","volume":"19","author":"Jalalat","year":"2013","journal-title":"Dermatol Online J"},{"key":"2026092208161199300_llag350-B22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2340\/00015555-1289","article-title":"Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib","volume":"92","author":"Brazzelli","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"2026092208161199300_llag350-B23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jocd.12517","article-title":"Cytokine profile (IL-2, IL-6, IL-17, IL-22, and TNF-\u03b1) in vitiligo \u2013 new insight into pathogenesis of disease","volume":"18","author":"Sushama","year":"2019","journal-title":"J Cosmet Dermatol"},{"key":"2026092208161199300_llag350-B24","doi-asserted-by":"crossref","first-page":"1455050","DOI":"10.3389\/fimmu.2024.1455050","article-title":"Biologic drugs induced vitiligo: case reports and review of literature","volume":"15","author":"Shao","year":"2024","journal-title":"Front Immunol"},{"key":"2026092208161199300_llag350-B25","first-page":"1669","article-title":"Two cases of dupilumab-induced vitiligo","volume":"22","author":"Ferreirinha","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026092208161199300_llag350-B26","doi-asserted-by":"crossref","first-page":"e13347","DOI":"10.1111\/dth.13347","article-title":"New-onset vitiligo in a patient with hidradenitis suppurativa treated with adalimumab","volume":"33","author":"Phan","year":"2020","journal-title":"Dermatol Ther"},{"issue":"3 Suppl.","key":"2026092208161199300_llag350-B27","doi-asserted-by":"crossref","first-page":"AB219","DOI":"10.1016\/j.jaad.2022.06.906","article-title":"Vitiligo associated with mogamulizumab","volume":"87","author":"Serrano","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026092208161199300_llag350-B28","doi-asserted-by":"crossref","first-page":"e15872","DOI":"10.1111\/dth.15872","article-title":"Generalized vitiligo in a psoriatic patient treated with ixekizumab","volume":"35","author":"Pathmarajah","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026092208161199300_llag350-B29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1684\/ejd.2021.4002","article-title":"Mogamulizumab-induced vitiligo in patients with S\u00e9zary syndrome: three cases","volume":"31","author":"Algarni","year":"2021","journal-title":"Eur J Dermatol"},{"key":"2026092208161199300_llag350-B30","doi-asserted-by":"crossref","first-page":"e000239","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"key":"2026092208161199300_llag350-B31","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1111\/jdv.19132","article-title":"Vitiligo induced by dupilumab treatment: a case series","volume":"37","author":"Ren","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026092208161199300_llag350-B32","doi-asserted-by":"crossref","first-page":"omz134","DOI":"10.1093\/omcr\/omz134","article-title":"Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris","volume":"2020","author":"Palazzo","year":"2020","journal-title":"Oxf Med Case Reports"},{"key":"2026092208161199300_llag350-B33","first-page":"74","article-title":"Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod","volume":"33","author":"Mashiah","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"2026092208161199300_llag350-B34","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s13555-023-00978-0","article-title":"Rare cutaneous side effects of imiquimod: a review on its mechanisms, diagnosis, and management","volume":"13","author":"Zhang","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026092208161199300_llag350-B35","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/all.15538","article-title":"Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseases","volume":"78","author":"Pavel","year":"2023","journal-title":"Allergy"},{"key":"2026092208161199300_llag350-B36","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1038\/jid.2014.196","article-title":"Molecular characterization of human skin response to diphencyprone at peak and resolution phases: therapeutic insights","volume":"134","author":"Gulati","year":"2014","journal-title":"J Invest Dermatol"},{"key":"2026092208161199300_llag350-B37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12026-013-8482-z","article-title":"Systemic immunogenicity of para-phenylenediamine and diphenylcyclopropenone: two potent contact allergy-inducing haptens","volume":"58","author":"Svalgaard","year":"2014","journal-title":"Immunol Res"},{"key":"2026092208161199300_llag350-B38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000354767","article-title":"Diphenylcyclopropenone-induced vitiligo in a patient with alopecia universalis","volume":"5","author":"Riad","year":"2013","journal-title":"Case Rep Dermatol"},{"key":"2026092208161199300_llag350-B39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.47102\/annals-acadmedsg.V38N3p276","article-title":"Vitiligo as an adverse reaction to topical diphencyprone","volume":"38","author":"Pan","year":"2009","journal-title":"Ann Acad Med Singap"},{"key":"2026092208161199300_llag350-B40","doi-asserted-by":"crossref","first-page":"e15305","DOI":"10.1111\/dth.15305","article-title":"Segmental vitiligo following acitretin treatment for infantile generalized pustular psoriasis resulting in repigmentation under secukinumab therapy","volume":"35","author":"Yang","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026092208161199300_llag350-B41","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1590\/abd1806-4841.20142887","article-title":"Segmental vitiligo after infliximab use for rheumatoid arthritis \u2013 a case report","volume":"89","author":"Carvalho","year":"2014","journal-title":"An Bras Dermatol"},{"key":"2026092208161199300_llag350-B42","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1540-9740.2006.04772.x","article-title":"Segmental vitiligo and hair curling after interferon alpha and ribavirin treatment for hepatitis C","volume":"5","author":"Tinio","year":"2006","journal-title":"Skinmed"},{"key":"2026092208161199300_llag350-B43","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1365-4632.2009.04443.x","article-title":"Interferon-induced vitiligo in hepatitis C patients: a case series","volume":"49","author":"Hamadah","year":"2010","journal-title":"Int J Dermatol"},{"key":"2026092208161199300_llag350-B44","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000320207","article-title":"Vitiligo at injection site of PEG-IFN-alpha 2a in two patients with chronic hepatitis C: case report and literature review","volume":"2","author":"Arya","year":"2010","journal-title":"Case Rep Dermatol"},{"key":"2026092208161199300_llag350-B45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/10781552211027936","article-title":"A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient","volume":"28","author":"Gratiaux","year":"2022","journal-title":"J Oncol Pharm Pract"},{"issue":"Suppl. 2","key":"2026092208161199300_llag350-B46","doi-asserted-by":"crossref","first-page":"S896","DOI":"10.4103\/jcrt.jcrt_2037_21","article-title":"Temozolomide-induced vitiligo-like reaction: an extremely rare phenomenon","volume":"19","author":"Madan","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"2026092208161199300_llag350-B47","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(01)06650-8","article-title":"Clinical picture: leopard-like vitiligo with capecitabine","volume":"358","author":"Schmid-Wendtner","year":"2001","journal-title":"Lancet"},{"key":"2026092208161199300_llag350-B48","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/rheumatology\/31.11.790","article-title":"Chloroquine-induced vitiligo in a patient with juvenile onset rheumatoid arthritis","volume":"31","author":"Gonggryp","year":"1992","journal-title":"Br J Rheumatol"},{"key":"2026092208161199300_llag350-B49","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1067\/mjd.2003.53","article-title":"Chloroquine-induced, vitiligo-like depigmentation","volume":"48","author":"Mart\u00edn-Garc\u00eda","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"2026092208161199300_llag350-B50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2340\/0001555576166167","article-title":"A case report and review of the literature","volume":"76","author":"Selvaag","year":"1996","journal-title":"Acta Derm Venereol"},{"key":"2026092208161199300_llag350-B51","doi-asserted-by":"crossref","first-page":"e13007","DOI":"10.1111\/dth.13007","article-title":"Sulfasalazine-induced generalized vitiligo in a patient with dermatitis herpetiformis and celiac disease","volume":"32","author":"Turkowski","year":"2019","journal-title":"Dermatol Ther"},{"key":"2026092208161199300_llag350-B52","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jdcr.2022.06.003","article-title":"Vitiligo of the arm after COVID-19 vaccination","volume":"28","author":"Singh","year":"2022","journal-title":"JAAD Case Rep"},{"key":"2026092208161199300_llag350-B53","doi-asserted-by":"crossref","first-page":"116","DOI":"10.66344\/jpad.v33i1.2067","article-title":"Adverse cutaneous reactions post COVID-19 vaccination \u2013 case series from a tertiary care centre in Eastern India","volume":"33","author":"Agrawal","year":"2023","journal-title":"J Pak Assoc Dermatol"},{"key":"2026092208161199300_llag350-B54","first-page":"e20902","article-title":"Vitiligo possibly triggered by COVID-19 vaccination","volume":"14","author":"Militello","year":"2022","journal-title":"Cureus"},{"key":"2026092208161199300_llag350-B55","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/derm.2023.0161","article-title":"Severe localized vitiligo following phototoxicity to hydrochlorothiazide","volume":"35","author":"Ouni","year":"2024","journal-title":"Dermatitis"},{"key":"2026092208161199300_llag350-B56","first-page":"129","article-title":"Vitiliginous lesions induced by amyl nitrite exposure","volume":"91","author":"Vine","year":"2013","journal-title":"Cutis"},{"key":"2026092208161199300_llag350-B57","first-page":"201","article-title":"Non-recurrence of carbamazepine induced vitiligo after rechallenge with carbamazepine","volume":"8","author":"Saeedloo","year":"2013","journal-title":"Iran J Psychiatry"},{"key":"2026092208161199300_llag350-B58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdcr.2022.05.042","article-title":"Carbamazepine-induced reversible vitiligo","volume":"26","author":"Assaedi","year":"2022","journal-title":"JAAD Case Rep"},{"key":"2026092208161199300_llag350-B59","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jaad.2025.03.021","article-title":"Vitiligo development following COVID-19 vaccination: a retrospective analysis of 128 cases using the Vaccine Adverse Events Reporting System","volume":"93","author":"Pathak","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"2026092208161199300_llag350-B60","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12916-023-03049-5","article-title":"Incidence of immune-mediated inflammatory diseases following COVID-19: a matched cohort study in UK primary care","volume":"21","author":"Syed","year":"2023","journal-title":"BMC Med"},{"key":"2026092208161199300_llag350-B61","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.2147\/CCID.S439045","article-title":"Impact of COVID-19 vaccine and COVID-19 infection on vitiligo activity and progression","volume":"16","author":"Shi","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2026092208161199300_llag350-B62","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/ajd.70027","article-title":"New-onset vitiligo and change in disease status following COVID-19 vaccination and COVID-19 infection \u2013 an online survey","volume":"67","author":"Islam","year":"2026","journal-title":"Australas J Dermatol"},{"key":"2026092208161199300_llag350-B63","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag350\/70543786\/llag350.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag350\/70543786\/llag350.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:16:26Z","timestamp":1790079386000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/advance-article\/doi\/10.1093\/ced\/llag350\/8756585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":63,"URL":"https:\/\/doi.org\/10.1093\/ced\/llag350","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"article-number":"llag350"}}